FPH updates FY26 revenue and earnings guidance

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare updates FY26 revenue and earnings guidance

Auckland, New Zealand, 23 February 2026 – Fisher & Paykel Healthcare Corporation Limited
announced today that it has updated its revenue and earnings guidance for the financial year ending 31
March 2026.

The full-year guidance previously provided on 29 November 2025, based on a NZ:US exchange rate of
57 cents, was for operating revenue to be in the range of approximately $2.17 billion to $2.27 billion and
full-year net profit after tax to be in the range of approximately $410 million to $460 million.

At 31 January exchange rates*, the company now expects full year operating revenue to be
approximately $2.30 billion, and net profit after tax is expected to be in the range of approximately $450
million to $470 million. This updated guidance does not incorporate any potential refund of US tariffs
paid to date during the 2026 financial year.

“We have continued to see good growth across the full range of our Hospital products so far during our
second half,” said Lewis Gradon, Managing Director and CEO.

“While relative seasonal respiratory hospitalisations in the Northern Hemisphere winter may continue to
impact the second half result, our performance to date suggests pleasing progress in our efforts to
change clinical practice. Continuous improvement activities and other efficiency gains are also
contributing to improvements in our gross margin and operating margin,” said Mr Gradon.

The company also notes that the United States Supreme Court announced it has invalidated tariffs
imposed by the US administration under the International Emergency Economic Powers Act (IEEPA).
There are still a number of uncertainties regarding the implications of the Supreme Court’s ruling for
companies that import into the United States. The company continues to work through the complexities
associated with the US court rulings, refund processes and application of free trade agreements and
the Nairobi Protocol to its products, and will provide an update on tariff impacts with its full year results
at the end of May.

The company continues to view current and proposed tariff structures in the context of cost increases
that will be mitigated over time by the company’s longstanding continuous improvement activities. As
such, the company does not currently believe these matters have any material impact on the
company’s long-term direction, strategy or sustainable profitable growth.

* At 31 January 2026 exchange rates of NZD:USD 0.60, NZD:EUR 0.51, NZD:MXN 10.44.

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems
for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The
company’s products are sold in over 120 countries worldwide. For more information about the company,
visit our website www.fphcare.com.

Contacts:
Media Investors
Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 (0) 21 713 911
Dan Adolph
Head of Investor Relations
daniel.adolph@fphcare.co.nz
+64 (0) 22 511 4050

Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.